How should I treat an inflated trapped intra-coronary balloon?
04 Apr 2018
A 73-year-old male presented with acute chest pain and ST segment elevation in the inferior leads. Angiography revealed an occlusion of the mid right coronary artery. A drug-eluting stent was deployed and post-dilated throughout with a non-compliant balloon. However, the deflated balloon could not be retracted and became trapped in the proximal RCA...
Direct oral anticoagulants in addition to antiplatelet therapy for secondary prevention after acute coronary syndromes
22 Mar 2018
Cardio Poll: How will the SMART DATE study results impact your clinical practice?
The recent SMART-DATE trial ultimately showed non-inferiority for MACE of 6 months vs. 12 months DAPT in ACS patients treated with current generation DES. Yet, myocardial infarction (a secondary endpoint) was increased by 1% in the short DAPT group and no difference for stent thrombosis and major bleeding was observed between the two treatment arms.
6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial
15 Mar 2018
SMART-DATE: 6-month versus 12-month or longer DAPT after PCI in patients with acute coronary syndrome - a randomised, open-label, non-inferiority trial
13 Mar 2018
The SMART DATE trial presented at ACC1.8 and published simultaneously in the Lancet is yet another trial evaluating the duration of antiplatelet therapy in patients with acute coronary syndrome (ACS).
SECURE PCI: Loading Doses of Atorvastatin versus Placebo in Patients with ACS and planned revascularisation
12 Mar 2018
SECURE PCI evaluated if high dose of atorvastatin used before and after PCI might reduce cardiovascular events compared to placebo.
ODYSSEY Outcomes: Cardiovascular outcomes with alirocumab after acute coronary syndrome
11 Mar 2018
Patients with ACS experience adverse events despite guideline recommended care. This reiterates the need for additional therapy to address this problem in addition to standard care. Alirocumab in ODYSSEY Outcomes, the first trial conducted exclusively in ACS patients, provides promise with 15% reduction in MACE events.
Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: results from the German prospective, multicenter FITT-STEMI trial
15 Feb 2018
High bleeding risk patients: from clinical evidence to routine practice
25 Jan 2018 - From ASIAPCR/SINGLIVE 2018
Chairpersons: P.J.L. Ong , P. Urban
Objectives: To understand the criteria for high bleeding risk patients and to identify these patients in clinical practice, to discuss how the latest cutting-edge clinical evidence gives physicians the freedom to treat high bleeding risk patients, to discuss tailoring DAPT duration to the needs of different patient populations.
LIVE case: PCI for a patient with Ostial LAD disease with high bleeding risk
From ASIAPCR/SINGLIVE 2018
Consult this LIVE case on PCI for a patient with Ostial LAD disease with high bleeding risk, that includes a LIVE demonstration from the National Heart Centre - Singapore: 63-year-old male.